{"id":58603,"date":"2024-02-27T18:46:43","date_gmt":"2024-02-27T18:46:43","guid":{"rendered":"https:\/\/medsname.com\/olanzoop\/"},"modified":"2026-04-30T10:24:11","modified_gmt":"2026-04-30T10:24:11","slug":"olanzoop","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/olanzoop\/","title":{"rendered":"Olanzoop"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Snabbt svar<\/h3>\n

Olanzoop (Olanzapine 5 \/ 10 mg) is an atypical antipsychotic for schizophrenia, bipolar mania and maintenance, treatment-resistant depression (with fluoxetine), and acute agitation. The most robust antipsychotic effect of the atypicals \u2014 but the heaviest metabolic burden.<\/p>\n<\/div>\n

\nVad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade kundrecensioner<\/a>\n<\/div>\n

\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n

Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n

Olanzoop at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 arbetsdagar leveranstid eller vi skickar om utan extra kostnad \u2014 och kvalificerar sig f\u00f6r v\u00e5rt kundlojalitetsprogram<\/a>. V\u00e4rldsomsp\u00e4nnande leverans \u00e4r tillg\u00e4nglig till de flesta destinationer.<\/p>\n

What Olanzoop is and how it works<\/h2>\n

Olanzoop is an olanzapine tablet supplied by Cipla. Available strengths: 5 \/ 10 mg<\/strong>. Olanzapine is a thienobenzodiazepine atypical antipsychotic with strong D2 antagonism, strong 5-HT2A antagonism, and substantial H1 (sedation, weight gain), M1 (anticholinergic), and \u03b11 (orthostasis) blockade. The H1+M1 receptor profile is responsible both for its calming\/sedative effect (useful in acute agitation) and for its metabolic burden.<\/p>\n

Indikationer och dosering<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indikation<\/th>\nStartdos<\/th>\nM\u00e5lgrupp<\/th>\nMax<\/th>\n<\/tr>\n<\/thead>\n
Schizofreni (vuxen)<\/td>\n5\u201310 mg OD<\/td>\n10\u201320 mg en g\u00e5ng dagligen<\/td>\n20 mg<\/td>\n<\/tr>\n
Schizofreni (ungdomar \u2265 13 \u00e5r)<\/td>\n2.5\u20135 mg OD<\/td>\n10 mg OD<\/td>\n20 mg<\/td>\n<\/tr>\n
Bipol\u00e4r mani (vuxna)<\/td>\n10\u201315 mg en g\u00e5ng dagligen<\/td>\n10\u201320 mg en g\u00e5ng dagligen<\/td>\n20 mg<\/td>\n<\/tr>\n
Acute agitation (IM)<\/td>\n10 mg IM<\/td>\n\u2014<\/td>\n3 doser\/24h<\/td>\n<\/tr>\n
Treatment-resistant depression (with fluoxetine)<\/td>\n5 mg + 20 mg fluoxetine<\/td>\n5\u201318 mg<\/td>\n18 mg<\/td>\n<\/tr>\n
\u00c4ldre vuxna<\/td>\n2.5\u20135 mg OD<\/td>\n5\u201310 mg OD<\/td>\nefter tolerans<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Viktiga s\u00e4kerhets\u00f6verv\u00e4ganden<\/h2>\n
\nFDA svart l\u00e5da \u2013 demensrelaterad psykos<\/strong><\/p>\n

Alla atypiska antipsykotiska l\u00e4kemedel b\u00e4r en FDA svart l\u00e5da-varning f\u00f6r \u00f6kad d\u00f6dlighet (fr\u00e4mst kardiovaskul\u00e4r och infektionsrelaterad) n\u00e4r de anv\u00e4nds f\u00f6r att behandla beteendest\u00f6rningar hos \u00e4ldre med demens. Atypiska antipsykotika \u00e4r inte godk\u00e4nda f\u00f6r demensrelaterad psykos eller agitation<\/strong>. Anv\u00e4ndning i denna population \u00e4r off-label, sista utv\u00e4g, tidsbegr\u00e4nsad och kr\u00e4ver explicit risk-nyttosamtal.<\/p>\n<\/div>\n

\nHeaviest metabolic burden of the atypicals<\/strong><\/p>\n

Olanzapine produces the most weight gain (typically 4\u201310 kg in the first 6 months, sometimes far more), the most insulin resistance, and the most lipid disturbance of any commonly-used antipsychotic. Patients can develop type 2 diabetes within months of initiation. Mandatory monitoring: weight at every visit; fasting glucose \/ HbA1c and fasting lipids at baseline, 12 weeks, then 6-monthly.<\/strong> Counsel about diet and exercise from initiation.<\/p>\n<\/div>\n

\nSedation and anticholinergic burden<\/strong><\/p>\n

Strong sedation in the first 1\u20132 weeks. Anticholinergic effects (dry mouth, constipation, urinary hesitancy) are universal. Both lessen but do not disappear.<\/p>\n<\/div>\n

\nOlanzapine + benzodiazepine IM \u2014 caution<\/strong><\/p>\n

Combining IM olanzapine with parenteral benzodiazepines has produced cases of severe hypotension, respiratory depression, and death. If both are clinically necessary in acute agitation, separate by \u2265 1 hour and monitor closely.<\/p>\n<\/div>\n

Vanliga biverkningar<\/h2>\n